BioCentury | Apr 7, 2008
Finance

2Q milestones

...Sucampo (NASDAQ:SCMP)/ Takeda (Tokyo:4502) Amitiza lubiprostone (SPI-0211) Constipation-predominant irritable bowel syndrome (IBS) PDUFA date 4/29/08 Symbollon...
BioCentury | Mar 17, 2008
Company News

Symbollon, Xi’an Maidefa Pharmaceutical Co. Ltd. deal

...Symbollon will acquire 64% of Xi’an for $1.5 million in stock. Symbollon also will receive an...
...purchase the rest of Xi’an for cash. The acquisition is expected to close next month. Symbollon...
...cash flow from Xi’an’s 2008 revenues and access to the Chinese market for Symbollon’s products. Symbollon’s...
BioCentury | Jan 7, 2008
Finance

Late stage milestones

...NDA Apr 08 (data); 2H08 (NDA) Somaxon (NASDAQ:SOMX) Silenor doxepin (SO-101) Insomnia Submit NDA 1Q08 Symbollon...
BioCentury | Jun 25, 2007
Clinical News

IoGen: Completed Phase III enrollment

...U.S. Phase III trial of IoGen to treat moderate to severe pain associated with FBD. Symbollon...
BioCentury | Jan 8, 2007
Finance

Late stage milestones

...Insomnia Submit NDA 3Q07 Sonus (SNUS)/Schering (FSE:SCH; SHR) Tocosol paclitaxel Breast cancer Submit NDA YE07 Symbollon...
BioCentury | Sep 4, 2006
Company News

Gardent Pharmaceuticals Inc., Symbollon, Switch Pharma deal

...The deal is expected to close Sept. 30. Gardent Pharmaceuticals Inc. (GRDP), New York, N.Y. Symbollon Pharmaceuticals Inc....
BioCentury | Jun 20, 2005
Company News

Symbollon management update

Symbollon Pharmaceuticals Inc. (SYMBA), Framingham, Mass. Business: Musculoskeletal Promoted: Paul Desjourdy to CEO from COO, while remaining president and CFO; he replaces Jack Kessler, who will remain chairman and CSO WIR Staff Musculoskeletal...
BioCentury | Apr 18, 2005
Company News

Bioaccelerate, Symbollon deal

...commercialization expenses and the companies will share profits. Bioaccelerate Holdings Inc. (BACL), New York, N.Y. Symbollon Pharmaceuticals Inc....
BioCentury | Jan 3, 2005
Clinical News

IoGen: Started Phase III

...to conservative treatment. Patients will receive 6 mg IoGen or placebo daily for 6 months. Symbollon...
BioCentury | Dec 22, 2004
Clinical News

Symbollon starts IoGen Phase III

SYMBA began a double-blind, placebo-controlled Phase III trial of its IoGen molecular iodine to treat moderate to severe periodic breast pain associated with fibrocystic breast disease. The trial will enroll 175 euthyroid premenopausal females with...
Items per page:
1 - 10 of 20
BioCentury | Apr 7, 2008
Finance

2Q milestones

...Sucampo (NASDAQ:SCMP)/ Takeda (Tokyo:4502) Amitiza lubiprostone (SPI-0211) Constipation-predominant irritable bowel syndrome (IBS) PDUFA date 4/29/08 Symbollon...
BioCentury | Mar 17, 2008
Company News

Symbollon, Xi’an Maidefa Pharmaceutical Co. Ltd. deal

...Symbollon will acquire 64% of Xi’an for $1.5 million in stock. Symbollon also will receive an...
...purchase the rest of Xi’an for cash. The acquisition is expected to close next month. Symbollon...
...cash flow from Xi’an’s 2008 revenues and access to the Chinese market for Symbollon’s products. Symbollon’s...
BioCentury | Jan 7, 2008
Finance

Late stage milestones

...NDA Apr 08 (data); 2H08 (NDA) Somaxon (NASDAQ:SOMX) Silenor doxepin (SO-101) Insomnia Submit NDA 1Q08 Symbollon...
BioCentury | Jun 25, 2007
Clinical News

IoGen: Completed Phase III enrollment

...U.S. Phase III trial of IoGen to treat moderate to severe pain associated with FBD. Symbollon...
BioCentury | Jan 8, 2007
Finance

Late stage milestones

...Insomnia Submit NDA 3Q07 Sonus (SNUS)/Schering (FSE:SCH; SHR) Tocosol paclitaxel Breast cancer Submit NDA YE07 Symbollon...
BioCentury | Sep 4, 2006
Company News

Gardent Pharmaceuticals Inc., Symbollon, Switch Pharma deal

...The deal is expected to close Sept. 30. Gardent Pharmaceuticals Inc. (GRDP), New York, N.Y. Symbollon Pharmaceuticals Inc....
BioCentury | Jun 20, 2005
Company News

Symbollon management update

Symbollon Pharmaceuticals Inc. (SYMBA), Framingham, Mass. Business: Musculoskeletal Promoted: Paul Desjourdy to CEO from COO, while remaining president and CFO; he replaces Jack Kessler, who will remain chairman and CSO WIR Staff Musculoskeletal...
BioCentury | Apr 18, 2005
Company News

Bioaccelerate, Symbollon deal

...commercialization expenses and the companies will share profits. Bioaccelerate Holdings Inc. (BACL), New York, N.Y. Symbollon Pharmaceuticals Inc....
BioCentury | Jan 3, 2005
Clinical News

IoGen: Started Phase III

...to conservative treatment. Patients will receive 6 mg IoGen or placebo daily for 6 months. Symbollon...
BioCentury | Dec 22, 2004
Clinical News

Symbollon starts IoGen Phase III

SYMBA began a double-blind, placebo-controlled Phase III trial of its IoGen molecular iodine to treat moderate to severe periodic breast pain associated with fibrocystic breast disease. The trial will enroll 175 euthyroid premenopausal females with...
Items per page:
1 - 10 of 20